Moderna Inc. stock: EUR 180.50, down 1.85% premarket
Published on 11/19/2026 at 07:51 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSModerna's Premarket Direction
- Moderna develops mRNA-based medicines and vaccines.
- Management recently highlighted oncology development and further clinical milestones.
Moderna Inc. stock traded at 180.50 euros on Lang & Schwarz at 07:50 CET on Thursday, November 19, 2026, 1.85 percent below the Xetra close of Wednesday, November 18, 2026, at 183.90 euros.
Moderna develops mRNA-based medicines and vaccines, while its oncology pipeline remains a central part of its growth strategy.
Broader market conditions can be followed through the S&P 500.
Disclaimer...
en | US60770K1079 | MODERNA INC. | boerse | 70534307 | bgmi
